Industries > Pharma > Top 50 Gastrointestinal Therapeutic Companies 2020

Top 50 Gastrointestinal Therapeutic Companies 2020

GlaxoSmithKline, Abbott, Allergan, Eli Lilly, Evoke Pharma, Other Companies

PUBLISHED: 04 October 2019
PAGES: 263
PRODUCT CODE: PHA0528
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0528 Categories: , Tags: , , ,

The gastrointestinal (GI) therapeutics industry is on the rise; growing to reach $68,237.0m by 2028. This growth stems from rising prevalence of GI disorders. Moreover, the increase in R&D has been a priority of the big pharma companies to infuse the drug pipelines with a new set of candidates with a high potential of reaching the clinical stage. However, the pricing pressure due to rising competition has hampered the market growth. On the contrary, the expiry of high-profile patents, which will carve the path for the launch of generic drugs in the market can provide growth opportunities to the other players in the market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 263-page report you will receive 116 charts– all unavailable elsewhere.

The 263-page report provides clear detailed insight into the leading 50 gastrointestinal therapeutic companies. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Our study discusses the selected leading companies that are the major players in the gastrointestinal drugs market:
• Abbott
• AbbVie
• Alexion Pharmaceuticals
• Allergan
• ANI Pharmaceuticals, Inc.
• AstraZeneca
• Bayer AG
• Biogen
• Eisai Co., Ltd.
• Eli Lilly
• Evoke Pharma
• GlaxoSmithKline
• Intercept Pharmaceuticals
• Ironwood Pharmaceuticals
• Janssen Pharmaceutica
• Kyowa Hakko Kirin Co. Ltd.
• Mallinckrodt plc
• Pfizer
• Synergy Pharmaceuticals Inc.
• Takeda
• Cadila Healthcare Ltd.
• Novartis AG
• Shire
• Merck & Co., Inc.
• Lexicon Pharmaceuticals, Inc.
• Sanofi
• ETX Pharma, Inc.
• Theravance Biopharma, Inc.
• Other companies

Top 50 Gastrointestinal Therapeutic Companies 2020

• This report also discusses factors that drive and restrain the market, as well as opportunities in the gastrointestinal therapeutic market.

Visiongain’s study is intended for anyone requiring commercial analyses for the leading 50 gastrointestinal therapeutic companies. You find data, trends and predictions.

Buy our report today Top 50 Gastrointestinal Therapeutic Companies: GlaxoSmithKline, Abbott, Allergan, Eli Lilly, Evoke Pharma, Other Companies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Top 50 Gastrointestinal Therapeutic Companies 2020


Download sample pages

Complete the form below to download your free sample pages for Top 50 Gastrointestinal Therapeutic Companies 2020


Latest Pharma news

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

READ

Categories